



OVERVIEW

Entos Pharmaceuticals Inc (Entos) is clinical state biotechnology company that develops genetic medicines using its Fusogenix drug delivery technology. Entos has active therapeutic development programs for vaccines, cancer therapeutics, and gene therapies for a wide range of diseases. Entos has developed two innovative DNA-based COVID-19 vaccine candidates, Covigenix VAX-001 and VAX-002. The first candidate, Covigenix VAX-001 is currently in an adaptive phase I/II clinical trial. The second candidate, Covigenix VAX-002, is set to enter clinical trials as a single-dose vaccine designed to induce pan-coronavirus immunity and provide durable protection against emerging SARS-CoV-2 variant strains.

Entos has partnered with the world's leading biotechnology and pharmaceutical companies to develop the next generation of safe, effective, stable, and re-dosable vaccines and therapeutics using Fusogenix technology. Fusogenix is a proteo-lipid vehicle (PLV) formulation, developed over the last ten years that uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology applies a wide range of therapeutic types, including gene therapy, plasmid DNA, mRNA, miRNA, RNAi, CRISPR, and small molecule drugs.

BUSINESS OBJECTIVE

Entos is looking to connect with additional partners interested in licensing its technology or partners that are interested in helping move its clinical development program forward.

For more information, visit <http://www.entospharma.com>

Contact:

John D. Lewis, Ph.D.

CEO, Entos Pharmaceuticals, Inc.

Email: john.lewis@entospharma.com